Unibest

Pharmaceutical intermediates

Trilaciclib hydrochloride Intermediates

2 pharmaceutical intermediates for Trilaciclib hydrochloride. Indication: Chemotherapy-Induced Myelosuppression.

Submit a ProjectAll intermediates

About Trilaciclib hydrochloride

Originator
G1 Therapeutics Inc
Indication
Chemotherapy-Induced Myelosuppression
Approved Date
02/12/2021
NCE Patent
10/25/2031
DS/DP
02/12/2026

Available intermediates

2 intermediates currently listed for Trilaciclib hydrochloride. Request specifications, documentation or a quotation for any item below.

Trilaciclib hydrochloride intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
Spiro[cyclohexane-1,9'(6'H)-pyrazino[1',2':1,5]pyrrolo[2,3-d]pyrimidine]-7'(8'H)-carboxylic acid, 2'-(methylthio)-6'-oxo-, 1,1-dimethylethyl ester2170746-99-1//
1-METHYL-4-(6-AMINOPYRIDIN-3-YL)PIPERAZINE571189-49-6//

Other programs under T

Tazemetostat HydrobromideTazobactam SodiumTegoprazanTenapanor HydrochlorideTeneligliptinTetrabenazineTezacaftorTianeptine sodium salt

Building toward Trilaciclib hydrochloride?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

Submit a Project Talk to the team

How can we help you?

Receive insights into the latest events and regulatory updates

Sent directly to your email

Get industry insights and Unibest news here

Contact Us →